ImmuPharma PLC (LSE:IMM),  the specialist drug discovery and development company, provides notification of changes to its Board of Directors. It has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform. Most recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration (“FDA”) on the new…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with systemic lupus erythematosus (“SLE/Lupus”) is to commence in H2 2023.  Key highlights: Following the receipt of comprehensive guidance from the Food and Drug Administration (“FDA”) in 3 separate…

To view warrants outstanding click here

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2022 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”), which is a further debilitating auto-immune condition within the Company’s P140 platform Key highlights: ImmuPharma has received positive support and guidance from the Food and…

TR-1: Standard form for notification of major holdings To view click here

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2022 (the “Period”). Key Highlights (including post Period review)  Financial Loss for the Period of £3.8m (2021: £8.2m) Research and development expenses of £2.0m (2021: £3.7m) Administrative expenses of £0.8m…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that  the Food and Drug Administration (“FDA”) has set a date of 7th June 2023 for a Type-C meeting to provide guidance on the Phase 2/3 adaptive study of Lupuzor™ (“P140”) in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”). Key highlights: ImmuPharma has received confirmation from the Food and Drug Administration (“FDA”) for a pre- Investigational New Drug meeting date of 16 May…